

**Addictions: from biology to recovery.
Translating research evidence to improve practice and community resilience.**

Sunday 4th October 2015

13.00-17.00

Registration and setting up of posters at the CAIRD HALL

Monday 5th October 2015

08.45

isamDUNDEE2015 Congress Opening Ceremony

09.30

INTRODUCTION: Addiction is addiction: Past, present and future. Chair: Kathleen Brady. Discussants: Raju Hajela, Stu Gitlow, Ken Roy

10.30

Coffee/Tea Break

11.00-11.20

SYP01: Drug and Alcohol Policy.
Symposium Lead: Peter Rice
Topic: Practitioners in the world of alcohol policy

Implementing the alcohol policy 'best buys': The Scottish experience.
Peter Rice

SYP02: Inequalities.
Symposium Lead: Kenneth Blum and Ken Roy
Topic: Genetic Testing in Addiction Medicine

Clinical applications of genetic testing in addiction medicine.
Kenneth Blum and Ken Roy

SYP03: Addiction Mechanisms.
Symposium Lead: Dai Stephens
Topic: Stimulants

Motivational effects of methylphenidate use are associated with GABA-variants conferring cocaine addiction risk.
Dai Stephens

SYP04: Inequalities.
Symposium Lead: Ilana Crome and Helge Waal
Topic: The ageing OMT patient

Morbidity and mortality in the ageing OMT patient.
Ivar Skeie

SYP05: Swiss Society of Addiction Medicine (SSAM).
Symposium Lead: Riaz Khan and Sebastian Saville
Topic: International Doctors for Healthier Drug Policies (IDHDP)/ (SSAM) joint symposium

Translating harm reduction into policy, the Swiss experience of Heroin Assisted Treatment (HAT).
Riaz Khan

SYP06: Behavioural Addictions.
Symposium Lead: Henrietta Bowden-Jones
Topic: Gambling disorder: International updates in aetiology and treatment

The Binge Gambling Screen. How to assess binge gamblers.
Henrietta Bowden-Jones

11.25-11.40

Adolescent substance use disorders - Is it different from adult onset substance use disorders?: An Indian experience.
Arun Kandasamy

Clinical considerations in genetic testing and personalized medicine.
Ken Roy

Early life stress alters expression of GABA_A receptors in nucleus accumbens and cocaine behaviour.
Jeremy Lambert

Experiences, thoughts and feelings in the late stages of life. A qualitative investigation.
Hege Nyhagen and Helge Waal

Out of the frying pan into the fire: How bad policies make drugs more harmful.
John Roche

Mediators of risk for gambling and comorbid disorders.
Nady el-Guebaly

11.45-12.00

The role of multi-sectoral action (MSA) in policy processes for reduction of harmful use of alcohol in Malawi.
Beatrice Mwangomba

Clinical Application of Genetic Addiction Risk Scale (GARS).
Mary P Hauser

Resting state brain connectivity using fMRI in patients with nicotine dependence.
Seon-Wan Ki

Treatment and care needs for the ageing OMT patient. A nation-wide investigation.
Sverre Nesvaag

Expert commissions for drug policy: what do they add?
Barbara Broers

Gender differences in clinical and psychopathological features of adolescents with high-risk for Internet addiction.
Ji Yoon Lee

12.05-12.20

Re-visitation of the diagnostic criteria for alcohol dependence in the ICD-10 using a sample of alcoholic subjects.
Atsushi Yoshimura

Genetic Addiction Risk Score (GARSTM) predicts Addiction Severity Index - MV alcohol and drug - risk scores in a Multi-centre study.
Kenneth Blum

Impaired control of interfering information in language and memory in chronic and recreational users of cocaine.
Manuel J Ruiz Munoz

Clinical guidelines on the ageing dependent population.
Ilana Crome

If we know how to safely reduce OD deaths - why don't we?
Chris Ford

A randomised, double-blind, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling.
Hannu Alho

12.25

PL01 David Goldberg: Injection drug use and blood borne viruses: is 2015 a watershed?

13.05

Lunch and Poster Session 1

14.30

PL02 Elizabeth Sáenz: Each person counts - UNODC's global projects on drug use prevention and the treatment of drug use disorders.

15.30-16.00

SYP07: Drug and Alcohol Policy.
Symposium Lead: Brian Kidd
Topic: Drug & alcohol policies-a suitable case for governance treatment?

Definition of harmful female drinking - it is not that simple.
Jan Gill

SYP08: Inequalities.
Symposium Lead: Graham Watt
Topic: Improving access and narrowing inequalities

Preventing and reducing health inequalities - the role of primary care.
Graham Watt

SYP09: Addiction Mechanisms.
Symposium Lead: Eliot L Gardner
Topic: Atypical dopamine transporter blockers as potential anti-addiction medications

Is modafinil an atypical dopamine transporter (DAT) blocker?
Michael H Baumann

SYP10: Recovery/Harm Reduction.
Symposium Lead: Kathleen Brady
Topic: Effective treatment modalities

The evidence-base, psychological mechanisms and optimisation of supervised disulfiram for 'difficult' alcoholic patients.
Colin Brewer

SYP11: European Federation of Addiction Societies (EUFAS).
Symposium Lead: Antoni Gual and Karl Mann
Topic: Harmonising alcohol policies and treatment guidelines throughout Europe.

Redesigning addiction policy in Europe: Key findings of the Alice Rap project.
Antoni Gual

SYP12: Recovery/Harm Reduction.
Symposium Lead: Emily Jefferson
Topic: The use of routinely collected linked data for analysis of longitudinal addiction cohorts

Clean, reproducible provision of data for studying non-consented longitudinal addiction cohorts.
Emily Jefferson

16.00-16.15

Developing quality indicators for aftercare following intensive rehabilitation for alcohol dependence: a Delphi study.
Catharina Mathei

Fetal Alcohol Spectrum Disorders: Past, present and future.
Maira Plant

Dopamine transporter inhibitors: different pathways to a typicality.
Maarten E A Reith

Is Take-Home Naloxone an effective harm reduction strategy? A systematic review of the evidence using the Bradford Hill Criteria.
Rebecca McDonald

Norwegian guidelines for the treatment of substance use disorder.
Jorgen G Branness

Applying psychometric epidemiology principles in addiction and related research.
Timothy Croudace

16.15-16.30

A significant reduction in use, hospital and out-patient events and costs following naltrexone implant treatment for problematic alcohol use in Western Australia.
George O'Neil

Content validation of measuring assessment of Alcohol Consumption Among Pregnant women (ACAP) questionnaire.
Nurul Ain Sharudin

Agonist replacement therapy for cocaine addiction - On the horizon?
Eliot Gardner

A Phase II clinical trial of buprenorphine maintenance treatment for methamphetamine dependency.
Schwann Shariatirad (ISAM Fellow)

New French clinical practice guidelines on alcohol misuse.
Henri-Jean Aubin







Investigating the effect of Alcohol Brief Interventions (ABI) within A&E departments.
Louise O'Rourke

Addictions: from biology to recovery. Translating research evidence to improve practice and community resilience.

Monday 5th October 2015

16.30-16.45	Correlates of criminal behavior in substance users. Results from NorCOMT: a national cohort study. Ingeborg Skjærø	Alcohol in pregnancy: validation of a sensitive pictogram questionnaire. Andrew Symon	Development and binding characterization of high-affinity modafinil analogues as potential antagonizers of cocaine subjective effects. Claus J Loland	Study of factors related to the dropouts in a methadone maintenance treatment programme in India: a retrospective review. Roshan Bhad (NISA-ISAM Fellow)	The German evidence-based guidelines for the treatment of alcoholism. Karl Mann	Adherence to prescribed acamprosate and 5 year mortality. Serenella Tolomeo 3 year risk in emergency healthcare utilisation in a treatment-seeking opioid dependent population with comorbid chronic pain. Cassie Higgins
16.45-17.00	4 years of compulsory treatment in Victoria, Australia – The Severe Substance Dependence Treatment Act (SSDTA). Martyn Lloyd-Jones	Alcohol dependence in women with antisocial behaviour. Andrei Kirpichenka (WHO-ISAM Fellow)		Benzodiazepine maintenance in Opiate Substitution Treatment (OST): Good or bad? Adam Bakker	Comparing new alcohol guidelines with the international gold standard. Colin Drummond	Excess mortality among opiate users: record linkage for 200,000 opiate users in England, 2005-2009. Tim Millar
17.00	Coffee/Tea Break					
17.30-18.30	PL03 – Howard Moss: The heterogeneity of alcohol dependence and the role of polysubstance abuse					
19.30	Civic Reception at Discovery Point					

Colour Key for Symposium Rooms:

Symposium Room 1		Symposium Room 2		Symposium Room 3	
Symposium Room 4		Symposium Room 5		Symposium Room 6	

All plenary lectures (Introduction/PL01-PL09) will take place in the Main Hall.

The Opening Session will take place in the Main Hall.

Poster Sessions will take place in the Poster Room (rear of Main Hall).

Lunch and Coffee/Tea breaks will take place in the Marrayat Hall.

**Addictions: from biology to recovery.
Translating research evidence to improve practice and community resilience.**

Tuesday 6th October 2015

08.15-09.10	Open 12-Step Meeting					
09.15	PL04 George Koob: Neurobiological mechanisms of addictions.					
10.15	Coffee/Tea Break					
10.45-11.05	<p>SYP13: Recovery/Harm Reduction. Symposium Lead: Christos Kouimtsidis Topic: What is the evidence supporting a change of the treatment paradigm of alcohol dependence? The role of structured preparation prior detoxification</p> <p>Evidence from the implementation of a structured intervention before detoxification The SPADe project. Christos Kouimtsidis</p>	<p>SYP14: Inequalities. Symposium Lead: John Saunders Topic: Vulnerabilities of youth addiction</p> <p>Compromised prefrontal cognitive control over emotional interference in adolescents with internet gaming disorder. Young-Chul Jung</p>	<p>SYP15: Addiction Mechanisms. Symposium Lead: David Lovinger Topic: Cannabinoids, alcohol and opioids</p> <p>Alcohol, cannabinoids, habit formation and corticostriatal synaptic plasticity. David Lovinger</p>	<p>SYP16: Comorbidity. Symposium Lead: Marta Torrens Topic: Clinical responses to comorbid conditions within addiction services</p> <p>Co-morbid depression and substance disorders: where are we? Marta Torrens</p>	<p>SYP17: American Society of Addiction Medicine (ASAM). Symposium Lead: Jeffrey Goldsmith Topic: Inter-Professional Collaboration: an ASAM and International Nurse Society in Addictions (IntNSA) joint symposium</p> <p>Modelling of inter-professional collaborative practice. Jeffrey Goldsmith</p>	<p>SYP18: Comorbidity. Symposium Lead: Jag Khalsa and Ivan Montoya Topic: HIV & co-occurring infections</p> <p>Management of infections (HIV, HCV) in drug abusing populations in incarceration. Jag H Khalsa</p>
11.10-11.25	<p>Laboratory evidence of the effect of repeated detoxifications. Theodora Duka</p>	<p>Internet addiction among allied health science students in Nepal. Sujan Babu Marahatta (Souter-ISAMDundee2015 Fellow)</p>	<p>Different roles for beta-arrestin 2 in morphine analgesia and reinforcement. Tim Hales</p>	<p>Flashbacks and Hallucinogen Persisting Perception Disorder (HPPD): clinical topics and treatment approach. Arturo G Lerner</p>	<p>Development of inter-professional collaborative practice. Jeffery Wilkins</p>	<p>New research on cocaine, HIV and heart disease. Lai Shenghan</p>
11.30-11.45	<p>Preclinical/animal studies on the effect of repeated detoxifications. Alexis Bailey</p>	<p>Is criminalisation of cannabis a deterrent to its use? Perspectives from young cannabis users in Nigeria. Osasuyi Dirisu (Souter-ISAMDundee2015 Fellow)</p>	<p>Neuropharmacological analysis of some synthetic cannabinoids 'legal highs'. Colin Davidson</p>	<p>Methamphetamine-induced mental disorders: challenges for assessment and treatment. Daniel Lubman</p>	<p>Global Addiction Project (GAaP) - an online international teaching classroom. Dana Murphy-Parker</p>	<p>HCV treatment in Opioid Substitution Therapy (OST) and PWID populations. Jan Tait</p>
11.50-12.05		<p>Impact of mobile e-health intervention on binge drinking in young people - an exploratory study. The D-ADRIANNA Project. Cristina Crocarno (Souter-ISAMDundee2015 Fellow)</p>	<p>Baclofen as a pharmacotherapy of alcohol dependence: a laboratory study of the underlying biobehavioral mechanisms. Mehdi Farokhnia (NIDA-ISAM Fellow)</p>	<p>Anabolic androgenic steroid dependence and accessible treatment in the addiction health care system – a case policy study. Helene Paus Aasen</p>	<p>The medium of MOOC and how it can bring together interprofessional collaboration - a case study. Carmel Clancy and Trish Hafford-Letchfield</p>	<p>How effective is Hepatitis B vaccination programme for clients of a drug consumption facility? Michael Specka</p>
11.50-12.05		<p>Values identification in adolescents from Cordoba, Argentina. Dario Gigena (ISAM Fellow)</p>	<p>Effect of baclofen on alcohol cue-induced craving: a functional MRI study. Vivek Benegal (WHO-ISAM Fellow)</p>		<p>The medium of MOOC and how it can bring together interprofessional collaboration - a case study. Carmel Clancy and Trish Hafford-Letchfield</p>	<p>Outcomes of methadone versus buprenorphine-naloxone combination among HIV positive opiate dependents on antiretroviral treatment in Malaysia: 24 weeks, open labelled, randomised, controlled trial. Rusdi Abd Rashid</p>
12.10	PL05 Trevor Robbins: Neurobehavioral mechanisms of addiction.					
13.05	Lunch and Poster Session 2 - Goldfish Bowl (Therapeutic Communities for Dummies)					
14.00	PL06 Wim van den Brink: Addiction and comorbid ADHD: epidemiology, treatment and prevention.					

Open 12-Step Meeting will take place in Symposium Room 6.

Goldfish Bowl (Therapeutic Communities for Dummies) will take place in Symposium Room 1.

Addictions: from biology to recovery. Translating research evidence to improve practice and community resilience.

Tuesday 6th October 2015

15.00-15.20	<p>SYP19: Drug and Alcohol Policy. Symposium Lead: Paul Griffiths Topic: Emerging patterns in drug use</p> <p>Emerging patterns in drug use in Europe: trends, methods and challenges. Paul Griffiths</p>	<p>SYP20: Inequalities. Symposium Lead: Harry Sumnall Topic: Prevention programmes in addiction</p> <p>Prevention programmes as a tool to reduce inequalities. Harry Sumnall</p>	<p>SYP21: Addiction Mechanisms. Symposium Lead: Wai Kwong Tang Topic: Neuropharmacology, neuroimaging and epidemiology of psychoactive substances abuse.</p> <p>Evidence of brain damage in chronic ketamine users – a brain imaging study. Wai Kwong Tang</p>	<p>SYP22: Recovery/Harm Reduction. Symposium Lead: Jonathan Chick Topic: Abstinence or reduction: new data for an old debate?</p> <p>Abstinence or reduction: new data for an old debate? Jonathan Chick</p>	<p>SYP23: European Addiction Treatment Association (EUROPAD) Symposium Lead: Icro Maremmanni Topic: Heroin addiction and related clinical problems.</p> <p>Chronic pain among women with history of sexual abuse, opiate addicted and non-addicted. Einat Peles</p>	<p>SYP24: Recovery/Harm Reduction. Symposium Lead: Martin Cheatle Topic: Prescription opioid abuse, addiction and opioid-related overdoses in the EU</p> <p>Managing pain in patients with a history of opioid use disorder. Martin Cheatle</p>	
15.25-15.40	<p>Meeting the clinical challenges of Novel Psychoactive Substances (NPS). Introducing project NEPTUNE: an evidence based approach to support clinicians to manage NPS. Owen Bowden-Jones</p>	<p>Suicide and harm reduction in aboriginal communities, Hudson Bay, Northern Canada. Arnold Hill</p>	<p>Neuropharmacology of novel psychoactive substances. Colin Davidson</p>	<p>Novel oral lyophilised buprenorphine: 'First-in-Patient' Phase II, clinical safety study (vs sublingual buprenorphine) - higher buprenorphine availability, lower proportionate norbuprenorphine levels and lesser respiratory depression. John Strang</p>	<p>Falling rates of prescription opioid abuse and death in the United States: Formulations and ramifications. Janetta Iwanicki</p>	<p>Prescription opioid abuse, addiction and opioid-related overdoses in the European Union. Blair Smith</p>	
15.45-16.00	<p>A tentative component analysis of Norjizak: an illicit drug in Iran. Mandana Sadeghi</p>	<p>The efficacy of psychosocial interventions to reduce sexual and drug blood borne virus risk behaviours among people who inject drugs: a systematic review and meta-analysis. Gail Gilchrist</p>	<p>Synergistic changes in behaviour and biochemistry following cocaine self-administration in HIV Tg and F344 rats. Scott E Hemby</p>	<p>Rapid opiate outpatient detoxification: A service evaluation of the lofexidine-based BristoL-regime: A novel 2 week resource-efficient detoxification with dramatically improved drug-free exits. Jan Melicher</p>	<p>Drug misuse trends in new patient presentations in NHS Lanarkshire from Europad-Radars data. Duncan Hill</p>	<p>Opioid risk assessment and mitigation. Lynn Webster</p>	
16.05-16.25	<p>Profiling illicit diazepam tablets for drug intelligence purposes. Mae MacDougall-Heasman</p>	<p>Spicy food preference and alcoholism in Korea. Sun-Gon Kim</p>	<p>New and emerging synthetic drugs abuse in China. Zhimin Liu</p>	<p>Unobserved 'home' induction onto buprenorphine: outcomes at year 7. Andrea Kermack (NIDA-ISAM Fellow)</p>	<p>Impact of medical and psychiatric comorbidity in the retention in a methadone maintenance treatment. Francina Fonseca</p>		
16.30-16.45	<p>Clinical and regulatory approaches to identify the abuse and dependence potential of CNS-active drugs. Pierre Geoffroy</p>	<p>Clinical characteristics of alcohol related criminals in Korea. Kye-Seong Lee</p>		<p>The use of implant naltrexone in pregnant opiate dependent patients: Preliminary findings examining health outcomes from conception to early childhood. Erin Kelly</p>	<p>Abuse liability of buprenorphine: Unintended consequences of maintenance on a treatment medication. Sandra D Comer</p>	<p>Alcohol use disorder patients: focusing on the role of past heroin, current cocaine and cannabis use, and bipolar disorder. Angelo G I Maremmanni</p>	<p>Utilisation of expert consensus guidelines and policies to reduce risk of abuse, addiction and opioid related fatalities. Cheatle, Smith & Webster</p>
17.00	Coffee/Tea Break						
18.00	ISAM Culture and Arts Festival launch at Duncan of Jordanstone College of Art and Design						

Colour Key for Symposium Rooms:

Symposium Room 1		Symposium Room 2		Symposium Room 3	
Symposium Room 4		Symposium Room 5		Symposium Room 6	

All plenary lectures (PL01-PL09) will take place in the Main Hall.

Poster Sessions will take place in the Poster Room (rear of Main Hall).

Lunch and Coffee/Tea breaks will take place in the Marrayat Hall.

**Addictions: from biology to recovery.
Translating research evidence to improve practice and community resilience.**

Wednesday 7th October 2015

08.15-09.10	Open 12-Step Meeting					
09.15	PL07 Nick Heather: Addiction as a disorder of choice.					
10.15	Coffee/Tea Break					
10.45-11.05	<p>SYP25: Comorbidity. Symposium Lead: Giuseppe Carra Topic: Clinical responses in psychiatry services to substance misuse</p> <p>Restoration of quality of life and cognitive dysfunction after out-patient management in internet gaming disorder. Jae A Lim</p>	<p>SYP26: Royal College of Psychiatrists (RCPsych) Addiction Faculty. Symposium Lead: Dr Sarah Welch Topic: Harnessing biology, sociology and psychology to promote recovery</p> <p>Introduction. Sarah Welch and Colin Drummond</p>	<p>SYP27: Education. Symposium Lead: Cornelis de Jong Topic: International aspects to medical education in substance misuse/addictions (1)</p> <p>The Medical Council on Alcohol (MCA); lessons learned from a case study of nearly 50 years of education on alcohol for doctors and medical undergraduates in the UK. Dominique Florin</p>	<p>SYP28: International Nurse Society in Addictions (IntNSA). Symposium Lead: Mike Flanagan Topic: Non-medical prescribing</p> <p>The development of non-medical prescribing in substance misuse services in the UK. Mike Flanagan and Rosie Mundt-Leach</p>	<p>SYP29: Drug and Alcohol Policy. Symposium Lead: Dr Gregory Bunt and Jag Khalsa Topic: Marijuana, addiction physicians and public policy – 2015 (1). Where does ISAM stand on this issue?</p> <p>Introducing the debate. Gregory Bunt</p>	<p>SYP30: Behavioural Addictions. Symposium Lead: Susumu Higuchi and Vladimir Poznyak Topic: Current controversies regarding internet use behaviours/ disorders</p> <p>Position of behavioural addictions in ICD-11. Karl Mann</p>
11.10-11.25	<p>Are the relationships between mental burden and alcohol misuse mediated by alcohol use expectancies among French soldiers? A structural equation modelling. Vanessa Marbac-Delon</p>	<p>Harnessing the power of contingency management. John Strang</p>	<p>How to deliver a national curriculum for undergraduate medical students and health care professionals. Christine Goodair and Ilana Crome</p>	<p>Non-Medical Prescribing: USA perspective. William Lorman</p>	<p>Impact upon morbidity and mortality secondary to wider use of marijuana. Stu Gitlow</p>	<p>Neurodevelopmental features of internet use and gaming problems. Marc Potenza</p>
11.30-11.45	<p>The association between cannabis use and depression - a longitudinal study. Shaul Lev-Rau</p>	<p>New findings from neuroimaging studies to understand neuropharmacology of addiction. Anne Lingford-Hughes</p>	<p>Competencies in addiction medicine. The Canadian journey. Nady el-Guebaly</p> <p>Pre-graduate addiction medicine teaching in Geneva: beyond seminars. Barbara Broers</p>	<p>Non Medical Prescribing (NMP) in Substance Misuse: the NHS Lanarkshire experience and resulting service redesign. Duncan Hill</p> <p>Non medical prescribing in addiction care in Holland: challenges and pitfalls. Christien Loth</p>	<p>Arrest without conviction: what is the harm to youth? Sharon Stancliff</p>	<p>Epidemiological findings and clinical features of Internet Use Disorders (IUDs). Hae-Kook Lee</p>
11.50-12.05	<p>Alcohol specific health literacy. Julia Sinclair</p>	<p>Effectiveness and organisation of addiction medicine training across the globe. Arnt Schellekens</p>	<p>Nurse practitioner run AOD clinics: An Australian perspective. Michelle Pitcaithly</p>	<p>Modelling medical marijuana: a review of state programs and the role of physicians. Arthur William (NIDA-ISAM Fellow)</p>	<p>Draft clinical description and diagnostic guidelines for Internet Use Disorder (IUD). Susumu Higuchi</p>	
12.10	PL08 Keith Humphreys: Mutual help and recovery from addiction.					
13.00	Lunch and Poster Session 3 - Goldfish Bowl (NA for Dummies)					
13.00	Peer support group meeting for ISAM Congress organisers					
14.00	ISAM General Assembly					

Open 12-Step Meeting will take place in Symposium Room 6.

Goldfish Bowl (NA for Dummies) will take place in Symposium Room 1.

Peer support group meeting for ISAM Congress organisers will take place in Symposium Room 3.

ISAM General Assembly will take place in Symposium Room 3.

Addictions: from biology to recovery. Translating research evidence to improve practice and community resilience.

Wednesday 7th October 2015

15.00-15.20	<p>SYP31: Recovery/Harm Reduction. Symposium Lead: Joshua D Lee Topic: Extended release naltrexone, methadone and buprenorphine. Research among community and criminal justice populations: comparative and cost effectiveness, dissemination and optimization research</p> <p>Extended Release Naltrexone (XR-NTX) opioid relapse prevention among US adult criminal justice system (CJS) outpatients: Cost-effectiveness outcomes. Joshua D Lee</p>	<p>SYP32: Drug and Alcohol Policy. Symposium Lead: Hamad Al-Ghaferi and Vladimir Poznyak Topic: Classification of substance use and related disorders in the draft ICD-11 revision</p> <p>Introduction. Hamad al-Ghaferi and Vladimir Poznyak</p>	<p>SYP33: Education. Symposium Lead: Jane Marshall and Cornelis de Jong Topic: International aspects to medical education in substance misuse/addictions (2)</p> <p>Training doctors to treat other doctors/healthcare professionals with addiction problems. Jane Marshall</p>	<p>SYP34: Recovery/Harm Reduction. Symposium Lead: Marc Galanter Topic: Narcotics Anonymous</p> <p>Spirituality based recovery from drug addiction in the 12 step Fellowship of Narcotic Anonymous. Marc Galanter, Michael Blackmore, Alisdair Young and Jane Nickels</p>	<p>SYP35: Drug and Alcohol Policy. Symposium Lead: Gregory Bunt and Jag Khalsa Topic: Marijuana, addiction physicians and public policy – 2015 (2). Where does ISAM stand on this issue?</p> <p>Introducing the second part of the debate. Jag Khalsa and Gregory Bunt</p>	<p>SYP36: Recovery/Harm Reduction. Symposium Lead: Thomas Clausen Topic: Naloxone distribution to prevent opioid overdoses; experienced success factors</p> <p>N-ALIVE prison release naloxone trial. Preliminary results and implications for future policy and practice. John Strang</p>
15.25-15.40	<p>Three randomized trials of XR-NTX and methadone with vs without patient navigation in US jails: aims, implementation issues and recruitment to date. Robert P. Schwartz and Joshua D Lee</p>	<p>Concepts, definitions and diagnostic guidelines for substance use and other addictive disorders in ICD-11. John Saunders</p>	<p>Professionals' training and knowledge about working with comorbid trauma and addiction. Ayna Johansen</p> <p>Illness Perception Questionnaire Addiction: An instrument to evaluate perception towards addiction. Astri Parawita Ayu</p>		<p>Medical consequences of marijuana and role of cannabinoids in medicine. Jag Khalsa</p>	<p>Estonian experience with Take Home Naloxone (THN). Maris Salekesin</p> <p>Nasal naloxone distribution as part of a national overdose prevention strategy. Philip Lobmaier</p>
15.45-16.00	<p>Two US and Norwegian parallel comparative effectiveness trials: XR-NTX vs buprenorphine in community treatment settings. John Rotrosen, Nikolaj Kunoe and Lars Tanum</p>	<p>Disorders due to substance use and related health conditions in ICD-11: taxonomy and field testing. Vladimir Poznyak</p>	<p>Diversity of training healthcare providers in addiction medicine. Jan Klimas (ISAM Fellow)</p> <p>Evaluation of addiction medicine training on detoxification by means of reviewing 16 vignettes. Mary Janssen-van Raay</p>		<p>Development of medications to treat cannabis use disorders. Ivan Montoya</p>	<p>Delivering overdose prevention and naloxone programme in the Highlands, Scotland. Lisa Ross</p>
16.05-16.20	<p>Outpatient induction onto XR-NTX using naltrexone-buprenorphine: feasibility and effectiveness. Paolo Mannelli</p> <p>Panel discussion: Assessing XR-NTX's effectiveness vs. pharmacotherapy standards of care.</p>	<p>Organization of field testing of ICD-11 in selected addiction centres of the Middle East . Tarek Gawad</p>	<p>Position paper on addiction medicine training in Europe. Barbara Broaers</p>		<p>Decriminalisation of marijuana use in the UK. David Nutt</p>	<p>Each person counts. UNODC work on opioid overdose prevention through naloxone distribution in low-middle income countries. Elisabeth Saenz</p>
16.25	PL09 Ian Gilmore: Alcohol Policies – do they work?					
18.30	isamDUNDEE2015 Congress Delegates leave Dundee to Guthrie Castle by coach					
19.30	isamDUNDEE2015 Congress Dinner (Guthrie Castle)					

Colour Key for Symposium Rooms:

Symposium Room 1		Symposium Room 2		Symposium Room 3	
Symposium Room 4		Symposium Room 5		Symposium Room 6	

All plenary lectures (PL01-PL09) will take place in the Main Hall.

Poster Sessions will take place in the Poster Room (rear of Main Hall).

Lunch and Coffee/Tea breaks will take place in the Marryat Hall.

**Addictions: from biology to recovery.
Translating research evidence to improve practice and community resilience.**

Thursday 8th October 2015

08.15-09.10		Open 12-Step Meeting			
09.15	14th CARES Conference Registration				
09.30	<p>14th CARES Annual Conference: Novel interventions in the substance misuse field. Introduction: Keith Matthews</p>	<p>SYP37: Education. Symposium Lead: Marc Galanter Topic: Postgraduate training in addiction medicine and psychiatry</p> <p>Residencies in addiction psychiatry. Marc Galanter</p>	<p>SYP38: Comorbidity. Symposium Lead: Jørgen G Bramness Topic: Amphetamine use: medical, psychiatric and social consequences</p> <p>Morbidity and mortality in incarcerated amphetamine users. Anders Hakansson</p>	<p>SYP39: Drug and Alcohol Policy. Symposium Lead: Muhammad Muhsin Ahmad Zahari Topic: Drug and alcohol policies in Asia (1)</p> <p>Capacity building initiatives for management of substance use disorders in South East Asian region: achievements, barriers and road ahead. SK Khandelwal, Rakesh Lal and Yatan Pal Singh Balhara (India)</p>	<p>SYP40: IntNSA. Symposium Lead: Carmel Clancy and Dana Murphy-Parker Topic: Role of nurses in recovery orientated treatment</p> <p>The history and role of addiction nursing: lessons from the UK and USA. Carmel Clancy and Dana Murphy-Parker</p>
	<p>Role of novel psychoactive and psychedelic substances as potential therapeutic agents in the field of addiction and psychiatry. David Nutt</p>	<p>Addressing training gaps through addiction medicine research education for medical students and physicians. Jan Klimas (ISAM Fellow)</p>	<p>Transition from amphetamine-induced psychosis to schizophrenia in a small clinical sample: rate and risk factors. Eline Borger Rognli</p>		<p>The emerging role of addiction nursing in Brazil. Divane de Vargas</p>
	<p>Recent developments in heroin assisted treatment. Wim van den Brink</p>	<p>Validating addiction medicine: certification and textbook. Nady el-Guebalay</p>	<p>Methamphetamine addiction pharmacotherapy: methylphenidate case series. Roman Gabrhelik</p>	<p>Drug policy review and Medical Assisted Treatment (MAT) in South East Asia. Mohd Hussain Habil (Malaysia), Muhammad Muhsin Ahmad Zahari (Malaysia), Al Bachri Husin (Indonesia), Apinun Aramrattana (Thailand)</p>	<p>Introducing the Irish Chapter of IntNSA: the first international chapter outside of North America and the role of addiction nursing. Peter Kelly</p> <p>The determinants of nurses' self-efficacy in the treatment of prescription drug abuse. Miriyam Farkash</p>
11.15	Coffee/Tea Break	<p>Postgraduate training in addiction psychiatry in the UK. Ilana Crome</p>		<p>Stimulant treatment of ADHD and comorbid amphetamine dependence. Maija Konstenius</p>	Coffee/Tea Break
11.30	<p>Ablative neurosurgery for drug addiction. Bomin Sun</p>				<p>Palliative Care in Addiction Treatment in Holland: practice based experiences. Dick van Etten</p>
12.15	<p>Questions and Discussions</p>				<p>Overview on current development of the state of the health care industry towards European Standards as related to the nursing workforce in the addiction area in Albania. Alma Pula</p>
12.30-14.00		Lunch and Poster Session 4			

Open 12-Step Meeting will take place in Symposium Room 6.

Addictions: from biology to recovery. Translating research evidence to improve practice and community resilience.

Thursday 8th October 2015

14.00	Evidence for Gabapentin treatment for alcohol and/or cannabis dependence. Barbara Mason	SYP41: Drug and Alcohol Policy. Symposium Lead: Dr Sharon L Stancliff Topic: UNGASS 2016: the voice of medicine	SYP42: Comorbidity. Symposium Lead: Dr Yifrah Kaminer Topic: Adolescent psychiatric comorbidity: Selective issues in depression, suicidal behaviour and early onset psychosis	SYP43: Drug and Alcohol Policy. Symposium Lead: TBC Topic: Drug and alcohol policies in Asia (2)	SYP44: IntNSA. Symposium Lead: Carmel Clancy and Dana Murphy-Parker Topic: Workforce and education
		UNGASS 2016 on the World Drug Problem: An introduction. Gregory Bunt	Cannabis use and psychosis. Yifrah Kaminer	Alcohol and opioid related issues in South Central Asia. Seyed Ramin Radfar, Ali Farhoudian, Mohammed Taghi Joghataei, Schwann Shariatirad, Alireza Norooz Parvis Asthar (Iran)	Introducing the CARN and CARN-AP. Dana Murphy-Parker
		Increased use of naloxone as part of the public health response to opioid overdose. Nicolas Clark	Update regarding treatment of comorbid depression and substance misuse. John Curry		Online web-based addictions curriculum for undergraduate nursing education. Charon Burda
		Use of cannabinoids in the treatment of opioid and alcohol dependence. Ahmed El Kashef	Opioid Maintenance Treatment and reduction in mortality and crime. Thomas Clausen	Treatment of co-occurring suicidal behaviour and substance misuse. David Goldston	Policy and practice of harm reduction in India. Ravinda Rao, Atul Ambekar, Sudhir Khandelwal
	Immunisation in the management of drug and alcohol dependence. George Koob	Why doctor should care about UNGASS on drugs? Oanh Khuat		Drug use in rural China. Marek Chawarski	Education/workforce competencies for addiction nursing - next steps globally. Carmel Clancy
	Concluding Remarks	Global implementation of harm reduction. Sharon Stancliff			
16.30-17.30	ISAMDundee2015 Congress Closing Ceremony				

Colour Key for Symposium Rooms:

Symposium Room 1		Symposium Room 2		Symposium Room 3	
Symposium Room 4		Symposium Room 5		Symposium Room 6	

CARES Annual Conference will take place in the Main Hall.

Poster Sessions will take place in the Poster Room (rear of Main Hall).

Lunch and Coffee/Tea breaks will take place in the Marryat Hall.

isamDUNDEE2015 Congress Closing Ceremony will be in the Main Hall.